LGALS9 and neoplasm: When engaged predominantly on TAMs and MDSCs, and triggered by ligands such as Galectin-9 or tumor-associated β-glucans, Dectin-1 signaling drives immunosuppressive reprogramming, leading to PGE2 and IL-1β production, T cell dysfunction, and resistance to checkpoint blockade.